Research opens door to new drug therapies for Parkinson’s disease
McGill University researchers have unlocked a new door to developing drugs to slow the progression of Parkinson’s disease. Collaborating teams led by Dr. Edward A. Fon at the Montreal Neurological Institute and Hospital -The Neuro, and Dr. Kalle Gehring in the Department of Biochemistry at the Faculty of Medicine, have discovered the three-dimensional structure of the protein Parkin.
By Richard Silverman and Erin Lafferty
(Faculty of Medicine, McGill)
Wonder why you keep hearing about so many new infectious diseases? How do we manage them? Come explore the perpetual arms race between humans and microbes as we both battle for survival in our modern world. This talk will be followed by a screening of the movie Contagion.
January 29, 2013 - Addiction to cigarettes, drugs and other stimulants has been linked in the past to the brain’s frontal lobes, but now there is scientific evidence that indicates where in the frontal cortex addiction takes hold and how. Addiction could be a result of abnormal communication between two areas of the frontal lobes linked to decision-making. The discovery will undoubtedly stimulate clinical work on new therapies for millions of people who suffer from addiction.
The research by lead authors Dr.
Systemic lupus erythematosus (SLE), commonly known as lupus, is an autoimmune disease in which the body's immune system attacks healthy tissue such as the skin, joints, kidneys and the brain, leading to inflammation and lesions. The disease affects about 1 in 2000 Canadians, particularly women. Previous research has suggested that lupus patients have an increased risk of developing cancer, particularly lymphoma. Lymphoma is a type of blood cancer that occurs when cells called lymphocytes, which usually help protect the body from infection and disease, begin growing and multiplying uncontrollably leading to tumor growth.